Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

PHASE4RecruitingINTERVENTIONAL
Enrollment

9,930

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions
Coronary Artery Disease
Interventions
DRUG

Clopidogrel treatment group

Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.

OTHER

No antiplatelet or anticoagulant group

Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Hallym University Kangnam Sacred Heart Hospital

OTHER

collaborator

Hallym University Medical Center

OTHER

collaborator

Hanyang University

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

collaborator

Kangbuk Samsung Hospital

OTHER

collaborator

Wonju Severance Christian Hospital

OTHER

lead

Seoul National University Hospital

OTHER